Back to Search
Start Over
Combination Therapy of Long-Acting Injectable Second-Generation Antipsychotics and Oral Antipsychotics
- Source :
- Journal of Clinical Psychopharmacology. 42:81-86
- Publication Year :
- 2021
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2021.
-
Abstract
- Background Although long-acting injectable antipsychotics (LAI-APs) have been considered as a monotherapeutic option in the maintenance treatment of schizophrenia, it has been recently reported that the combination therapy of LAI-APs and oral antipsychotics (OAPs) is common. Methods We conducted a retrospective chart review to examine the situation of the combination therapy of LAI second-generation antipsychotics (LAI-SGAs) and OAPs, and a questionnaire survey to investigate prescribers' attitudes toward the combination therapy. We included patients who received any LAI-SGAs for 1 month or longer and classified them into monotherapy and combination therapy groups. We collected information on age, sex, primary psychiatric diagnosis, and concomitant psychotropic medications. Results Of the 132 patients, 39 (29.5%) received the combination therapy of LAI-SGAs and OAPs. Long-acting injectable risperidone was significantly associated with receiving the combination therapy compared with LAI aripiprazole. Olanzapine was the most common OAP in combination with LAI-SGAs. Only 8 patients (20.5%) concurrently received the same type of OAPs as LAI-SGAs. More than 60% of the patients received OAP polypharmacy before the initiation of LAI-SGAs. The psychiatrists in charge prescribed LAI-SGAs mainly because of a concern about adherence, and OAPs mainly because of insufficient dose of LAI-SGAs, to patients in the combination therapy group. They estimated that adherence to OAPs in two thirds of the patients in the combination therapy group was 80% or higher. Conclusions The present study showed that the combination therapy of LAI-SGAs and OAPs is often conducted in real-world clinical practice. Considering the reason for the introduction of LAI-APs, clinicians should carefully monitor patients' adherence to OAPs concurrently used with LAI-APs.
- Subjects :
- Adult
Male
Olanzapine
medicine.medical_specialty
Combination therapy
Attitude of Health Personnel
viruses
Aripiprazole
MEDLINE
Drug Prescriptions
Medication Adherence
immune system diseases
Internal medicine
medicine
Humans
Pharmacology (medical)
Retrospective Studies
Polypharmacy
Risperidone
business.industry
virus diseases
Middle Aged
medicine.disease
Psychiatry and Mental health
Psychotic Disorders
Schizophrenia
Delayed-Action Preparations
Health Care Surveys
Concomitant
Drug Therapy, Combination
Female
business
Antipsychotic Agents
medicine.drug
Subjects
Details
- ISSN :
- 1533712X and 02710749
- Volume :
- 42
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Psychopharmacology
- Accession number :
- edsair.doi.dedup.....93f826c55fe6acb2c6eb054e8496de73